# Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

> **NCT00138203** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** vorinostat
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00138203
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00138203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00138203, "Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00138203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*